References

10.1186/s13045-025-01679-1

10.1186/s13045-025-01679-1 · External reference

10.1056/nejmoa061884

10.1056/nejmoa061884 · External reference

Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

10.1200/jco.2007.15.0375 · 2008 · External reference

10.3390/jcm13154476

10.3390/jcm13154476 · External reference

10.1056/nejmoa1504627

10.1056/nejmoa1504627 · External reference

10.1002/cncr.33142

10.1002/cncr.33142 · External reference

10.1016/s0140-6736(15)01281-7

10.1016/s0140-6736(15)01281-7 · External reference

10.1056/nejmoa1606774

10.1056/nejmoa1606774 · External reference

10.1016/s0140-6736(18)32409-7

10.1016/s0140-6736(18)32409-7 · External reference

10.1056/nejmoa1801005

10.1056/nejmoa1801005 · External reference

10.1056/nejmoa1810865

10.1056/nejmoa1810865 · External reference

10.1016/s1470-2045(20)30641-0

10.1016/s1470-2045(20)30641-0 · External reference

10.1056/nejmoa2202170

10.1056/nejmoa2202170 · External reference

10.1056/nejmoa2302983

10.1056/nejmoa2302983 · External reference

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

10.1016/s0140-6736(21)02098-5 · 2021 · External reference

10.5578/tt.2025041169

10.5578/tt.2025041169 · External reference

10.1001/jamaoncol.2018.3676

10.1001/jamaoncol.2018.3676 · External reference

Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50

10.1200/jco.21.00174 · 2021 · External reference

10.1016/j.biopha.2020.110621

10.1016/j.biopha.2020.110621 · External reference

10.1016/j.jtho.2016.11.2228

10.1016/j.jtho.2016.11.2228 · External reference

10.20517/cdr.2025.14

10.20517/cdr.2025.14 · External reference

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

10.1172/jci91190 · 2017 · External reference

10.3390/ijms241914521

10.3390/ijms241914521 · External reference

10.1186/s40425-019-0647-4

10.1186/s40425-019-0647-4 · External reference

10.1136/esmoopen-2020-000706

10.1136/esmoopen-2020-000706 · External reference

10.1001/jamaoncol.2019.2963

10.1001/jamaoncol.2019.2963 · External reference

10.1186/s13045-025-01732-z

10.1186/s13045-025-01732-z · External reference

10.1038/s41571-024-00932-9

10.1038/s41571-024-00932-9 · External reference

10.1158/2159-8290.cd-20-0522

10.1158/2159-8290.cd-20-0522 · External reference

FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors

10.1158/1078-0432.ccr-21-0327 · 2021 · External reference

Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/Mismatch repair-deficient cancer: results from the phase ii KEYNOTE-158 study

10.1200/jco.19.02105 · 2020 · External reference

10.1001/jamaoncol.2022.1981

10.1001/jamaoncol.2022.1981 · External reference

10.1371/journal.pone.0263629

10.1371/journal.pone.0263629 · External reference

10.1097/md.0000000000034990

10.1097/md.0000000000034990 · External reference

10.1080/14796694.2024.2444862

10.1080/14796694.2024.2444862 · External reference

10.1016/j.annonc.2024.03.007

10.1016/j.annonc.2024.03.007 · External reference

10.1097/cm9.0000000000002181

10.1097/cm9.0000000000002181 · External reference

10.1126/science.aaa4971

10.1126/science.aaa4971 · External reference

10.3389/fimmu.2021.672356

10.3389/fimmu.2021.672356 · External reference

10.1126/science.aaa1348

10.1126/science.aaa1348 · External reference

10.1126/science.aaf1490

10.1126/science.aaf1490 · External reference

10.1038/s41591-024-03240-y

10.1038/s41591-024-03240-y · External reference

Phase iii KEYNOTE-789 study of Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor‒resistant, EGFR–mutant, metastatic Nonsquamous non–small cell lung cancer

10.1200/jco.23.02747 · 2024 · External reference

Checkpoint inhibitors in metastatic EGFR-Mutated non-small cell lung cancer-A meta-analysis

10.1016/j.jtho.2016.10.007 · 2017 · External reference

10.1001/jamaoncol.2017.4427

10.1001/jamaoncol.2017.4427 · External reference

10.1186/s12967-024-05456-5

10.1186/s12967-024-05456-5 · External reference

10.21037/tlcr-24-116

10.21037/tlcr-24-116 · External reference

10.1093/annonc/mdz167

10.1093/annonc/mdz167 · External reference

10.1136/jitc-2025-012288

10.1136/jitc-2025-012288 · External reference

10.1016/j.celrep.2023.113295

10.1016/j.celrep.2023.113295 · External reference

BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization

10.1158/0008-5472.can-14-0061 · 2014 · External reference

Mutation of SMARCA4 induces cancer cell-intrinsic defects in the enhancer landscape and resistance to immunotherapy

10.1158/0008-5472.can-24-2054 · 2025 · External reference

10.1177/10668969261444670

10.1177/10668969261444670 · External reference

10.1186/s12885-021-08114-x

10.1186/s12885-021-08114-x · External reference

PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells

10.1158/0008-5472.can-22-3023 · 2023 · External reference

Loss of PTEN promotes resistance to T cell-mediated immunotherapy

10.1158/2159-8290.cd-15-0283 · 2016 · External reference

10.1186/s13046-022-02422-1

10.1186/s13046-022-02422-1 · External reference

10.1016/j.lungcan.2018.02.004

10.1016/j.lungcan.2018.02.004 · External reference

10.1016/j.lungcan.2021.07.016

10.1016/j.lungcan.2021.07.016 · External reference

10.3389/fphar.2022.817265

10.3389/fphar.2022.817265 · External reference

10.1186/s12943-018-0832-y

10.1186/s12943-018-0832-y · External reference

10.3389/fimmu.2023.1127071

10.3389/fimmu.2023.1127071 · External reference

10.1007/s40259-024-00700-2

10.1007/s40259-024-00700-2 · External reference

10.1038/s41586-021-03752-4

10.1038/s41586-021-03752-4 · External reference

10.1038/s43018-021-00292-8

10.1038/s43018-021-00292-8 · External reference

10.1038/s41568-019-0144-6

10.1038/s41568-019-0144-6 · External reference

10.1002/cam4.70670

10.1002/cam4.70670 · External reference

10.1016/j.celrep.2022.111647

10.1016/j.celrep.2022.111647 · External reference

10.3389/fimmu.2024.1476904

10.3389/fimmu.2024.1476904 · External reference

Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and Multiparametric single-cell analysis

10.1158/1078-0432.ccr-18-4142 · 2019 · External reference

LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes

10.1016/j.jtho.2017.01.019 · 2017 · External reference

10.1038/ncomms10501

10.1038/ncomms10501 · External reference

10.1016/j.xcrm.2024.101831

10.1016/j.xcrm.2024.101831 · External reference

10.1016/s1470-2045(22)00226-1

10.1016/s1470-2045(22)00226-1 · External reference

10.1038/s41588-024-01998-y

10.1038/s41588-024-01998-y · External reference

10.1016/j.xcrm.2023.101302

10.1016/j.xcrm.2023.101302 · External reference

10.1038/s41586-021-04057-2

10.1038/s41586-021-04057-2 · External reference

10.1186/s12967-024-05142-6

10.1186/s12967-024-05142-6 · External reference

10.1136/jitc-2023-007218

10.1136/jitc-2023-007218 · External reference

10.1186/s12943-024-02179-5

10.1186/s12943-024-02179-5 · External reference

10.2147/itt.s253581

10.2147/itt.s253581 · External reference

10.1136/jitc-2022-005509

10.1136/jitc-2022-005509 · External reference

Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

10.3389/fonc.2025.1665239 · 2025 · External reference

10.1038/s41591-018-0057-z

10.1038/s41591-018-0057-z · External reference

10.1016/j.immuni.2022.12.001

10.1016/j.immuni.2022.12.001 · External reference

10.1016/j.lungcan.2024.107991

10.1016/j.lungcan.2024.107991 · External reference

10.3389/fimmu.2025.1486329

10.3389/fimmu.2025.1486329 · External reference

10.1126/science.aao4572

10.1126/science.aao4572 · External reference

10.1080/2162402x.2025.2462386

10.1080/2162402x.2025.2462386 · External reference

10.1038/s41591-019-0639-4

10.1038/s41591-019-0639-4 · External reference

HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small cell lung cancer

10.1158/1078-0432.ccr-23-0604 · 2023 · External reference

10.1016/j.cell.2017.10.001

10.1016/j.cell.2017.10.001 · External reference

10.1038/s41588-024-01883-8

10.1038/s41588-024-01883-8 · External reference

COPD and immune checkpoint inhibitors for cancer: a literature review

10.2147/copd.s490252 · 2024 · External reference

10.1186/s12885-023-11366-4

10.1186/s12885-023-11366-4 · External reference

10.1186/s12885-025-13440-5

10.1186/s12885-025-13440-5 · External reference

10.3892/ol.2024.14243

10.3892/ol.2024.14243 · External reference

10.1093/immadv/ltaf031

10.1093/immadv/ltaf031 · External reference

10.1038/s41598-024-70611-3

10.1038/s41598-024-70611-3 · External reference

10.3390/cancers13246355

10.3390/cancers13246355 · External reference

10.1136/jitc-2023-007310

10.1136/jitc-2023-007310 · External reference

10.1371/journal.pone.0312605

10.1371/journal.pone.0312605 · External reference

10.21037/tlcr-21-214

10.21037/tlcr-21-214 · External reference

10.1164/rccm.201706-1110oc

10.1164/rccm.201706-1110oc · External reference

10.1002/ijc.32235

10.1002/ijc.32235 · External reference

10.3390/cancers16071251

10.3390/cancers16071251 · External reference

Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer

10.1164/rccm.201704-0795oc · 2018 · External reference

10.21873/invivo.12280

10.21873/invivo.12280 · External reference

10.1186/s12885-024-11902-w

10.1186/s12885-024-11902-w · External reference

10.3389/fimmu.2025.1627557

10.3389/fimmu.2025.1627557 · External reference

10.21037/jtd-2025-356

10.21037/jtd-2025-356 · External reference

10.2147/copd.s569504

10.2147/copd.s569504 · External reference

10.1016/j.jtho.2025.10.007

10.1016/j.jtho.2025.10.007 · External reference

10.1016/j.medj.2025.100996

10.1016/j.medj.2025.100996 · External reference

10.1172/jci.insight.157915

10.1172/jci.insight.157915 · External reference

10.1186/s12964-025-02332-7

10.1186/s12964-025-02332-7 · External reference

10.1002/cam4.7112

10.1002/cam4.7112 · External reference

10.1002/cncr.34958

10.1002/cncr.34958 · External reference

10.7759/cureus.29423

10.7759/cureus.29423 · External reference

10.3389/fimmu.2026.1757711

10.3389/fimmu.2026.1757711 · External reference

10.1001/jamaoncol.2019.5241

10.1001/jamaoncol.2019.5241 · External reference

10.1186/s12885-025-14894-3

10.1186/s12885-025-14894-3 · External reference

10.1186/s40001-025-03694-x

10.1186/s40001-025-03694-x · External reference

10.21873/anticanres.17892

10.21873/anticanres.17892 · External reference

10.1007/s00262-022-03281-7

10.1007/s00262-022-03281-7 · External reference

10.1183/23120541.00981-2023

10.1183/23120541.00981-2023 · External reference

10.21037/tlcr-2025-783

10.21037/tlcr-2025-783 · External reference

10.3390/ijms25126685

10.3390/ijms25126685 · External reference

10.3390/cancers14194813

10.3390/cancers14194813 · External reference

10.1126/science.aan3706

10.1126/science.aan3706 · External reference

10.1002/eji.201444972

10.1002/eji.201444972 · External reference

10.1016/j.cell.2014.03.011

10.1016/j.cell.2014.03.011 · External reference

10.1016/j.cell.2018.12.040

10.1016/j.cell.2018.12.040 · External reference

10.1093/annonc/mdy103

10.1093/annonc/mdy103 · External reference

10.1126/science.aad9358

10.1126/science.aad9358 · External reference

10.1001/jama.2017.12857

10.1001/jama.2017.12857 · External reference

10.1016/s1470-2045(17)30841-0

10.1016/s1470-2045(17)30841-0 · External reference

10.1158/2326-6066.cir-20-0051

10.1158/2326-6066.cir-20-0051 · External reference

10.1002/ctm2.70170

10.1002/ctm2.70170 · External reference

10.1016/j.iotech.2025.101066

10.1016/j.iotech.2025.101066 · External reference

Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer

10.1200/jco.23.01488 · 2024 · External reference

10.7150/thno.126091

10.7150/thno.126091 · External reference

10.1038/s41591-025-04186-5

10.1038/s41591-025-04186-5 · External reference

10.3390/cancers18121948

10.3390/cancers18121948 · External reference

10.1038/s41698-020-00138-z

10.1038/s41698-020-00138-z · External reference

10.3389/fimmu.2026.1849553

10.3389/fimmu.2026.1849553 · External reference

10.1126/science.aar6918

10.1126/science.aar6918 · External reference

10.1136/gutjnl-2023-330168

10.1136/gutjnl-2023-330168 · External reference

10.1038/nrmicro.2016.142

10.1038/nrmicro.2016.142 · External reference

10.3389/fimmu.2025.1614731

10.3389/fimmu.2025.1614731 · External reference

10.1126/science.aad3369

10.1126/science.aad3369 · External reference

10.1016/j.immuni.2012.04.011

10.1016/j.immuni.2012.04.011 · External reference

10.1038/s41586-025-09249-8

10.1038/s41586-025-09249-8 · External reference

10.3389/fmicb.2025.1632435

10.3389/fmicb.2025.1632435 · External reference

Augmenting antitumor immune responses with epigenetic modifying agents

2015 · External reference

10.1038/nature15520

10.1038/nature15520 · External reference

10.1016/j.cell.2017.10.022

10.1016/j.cell.2017.10.022 · External reference

10.18632/oncotarget.1542

10.18632/oncotarget.1542 · External reference

10.1093/annonc/mdz196

10.1093/annonc/mdz196 · External reference

10.3390/cancers14112626

10.3390/cancers14112626 · External reference

10.1016/j.lungcan.2022.08.004

10.1016/j.lungcan.2022.08.004 · External reference

10.1016/j.critrevonc.2024.104332

10.1016/j.critrevonc.2024.104332 · External reference

10.1038/nrclinonc.2013.110

10.1038/nrclinonc.2013.110 · External reference

10.1126/scitranslmed.3007094

10.1126/scitranslmed.3007094 · External reference

10.1038/s41598-022-05606-z

10.1038/s41598-022-05606-z · External reference

10.1007/s10147-017-1105-2

10.1007/s10147-017-1105-2 · External reference

10.1158/1078-0432.ccr-17-1341

10.1158/1078-0432.ccr-17-1341 · External reference

Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer

10.1158/0008-5472.can-18-1127 · 2019 · External reference

10.1056/nejmoa2215530

10.1056/nejmoa2215530 · External reference

10.1016/j.lungcan.2018.04.001

10.1016/j.lungcan.2018.04.001 · External reference

PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors

10.1016/j.cllc.2021.03.005 · 2021 · External reference

10.1038/srep31726

10.1038/srep31726 · External reference

10.3390/cancers11060835

10.3390/cancers11060835 · External reference

10.1016/j.lungcan.2018.08.007

10.1016/j.lungcan.2018.08.007 · External reference

10.1038/nature07242

10.1038/nature07242 · External reference

10.1038/onc.2014.254

10.1038/onc.2014.254 · External reference

10.3389/fonc.2016.00003

10.3389/fonc.2016.00003 · External reference

10.1093/jnci/djv303

10.1093/jnci/djv303 · External reference

10.18632/oncotarget.1948

10.18632/oncotarget.1948 · External reference

10.1016/j.cell.2010.08.012

10.1016/j.cell.2010.08.012 · External reference

10.4049/jimmunol.0803162

10.4049/jimmunol.0803162 · External reference

10.1177/1753425913489850

10.1177/1753425913489850 · External reference

10.1158/1078-0432.ccr-18-1981

10.1158/1078-0432.ccr-18-1981 · External reference

10.1016/j.ygeno.2019.11.019

10.1016/j.ygeno.2019.11.019 · External reference

10.1080/0284186x.2018.1465585

10.1080/0284186x.2018.1465585 · External reference

10.3390/cancers14194739

10.3390/cancers14194739 · External reference

10.1038/s41698-022-00262-y

10.1038/s41698-022-00262-y · External reference

10.1080/2162402x.2018.1452581

10.1080/2162402x.2018.1452581 · External reference

10.1136/jitc-2019-000376

10.1136/jitc-2019-000376 · External reference

10.1200/po-24-00790

10.1200/po-24-00790 · External reference

10.1136/jitc-2025-012270

10.1136/jitc-2025-012270 · External reference

10.1172/jci.insight.132334

10.1172/jci.insight.132334 · External reference

10.3390/biomedicines11020508

10.3390/biomedicines11020508 · External reference

10.1038/s41568-020-00299-w

10.1038/s41568-020-00299-w · External reference

10.1038/s41577-019-0264-y

10.1038/s41577-019-0264-y · External reference

10.3390/cells10113247

10.3390/cells10113247 · External reference

10.3389/fimmu.2025.1603855

10.3389/fimmu.2025.1603855 · External reference

10.3389/fimmu.2021.665133

10.3389/fimmu.2021.665133 · External reference

10.1038/s41586-018-0392-8

10.1038/s41586-018-0392-8 · External reference

10.1038/s41416-023-02491-9

10.1038/s41416-023-02491-9 · External reference

10.3389/fphar.2021.676399

10.3389/fphar.2021.676399 · External reference

10.1016/j.lungcan.2019.02.009

10.1016/j.lungcan.2019.02.009 · External reference

10.1136/bmjopen-2019-035031

10.1136/bmjopen-2019-035031 · External reference

10.1007/s12325-020-01229-w

10.1007/s12325-020-01229-w · External reference

10.1186/s12885-021-08194-9

10.1186/s12885-021-08194-9 · External reference

10.4143/crt.2021.1007

10.4143/crt.2021.1007 · External reference

10.1634/theoncologist.2018-0563

10.1634/theoncologist.2018-0563 · External reference

10.1186/s13045-023-01456-y

10.1186/s13045-023-01456-y · External reference

10.1111/cas.15964

10.1111/cas.15964 · External reference

10.1111/1759-7714.15191

10.1111/1759-7714.15191 · External reference

10.21037/jtd-20-3525

10.21037/jtd-20-3525 · External reference

10.1007/s00408-021-00474-2

10.1007/s00408-021-00474-2 · External reference

Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with Nivolumab

10.1016/j.jtho.2017.10.030 · 2018 · External reference

10.3390/biom15040491

10.3390/biom15040491 · External reference

10.1016/j.critrevonc.2021.103374

10.1016/j.critrevonc.2021.103374 · External reference

10.1136/bmj.k3529

10.1136/bmj.k3529 · External reference

Advances in artificial intelligence to predict cancer immunotherapy efficacy

10.3389/fimmu.2022.1076883 · 2022 · External reference

10.1016/j.canlet.2025.217881

10.1016/j.canlet.2025.217881 · External reference

10.1158/2159-8290.cd-23-0277

10.1158/2159-8290.cd-23-0277 · External reference

10.1002/ctm2.70579

10.1002/ctm2.70579 · External reference

10.7759/cureus.61220

10.7759/cureus.61220 · External reference

10.1016/j.critrevonc.2024.104479

10.1016/j.critrevonc.2024.104479 · External reference

10.1148/radiol.2020191145

10.1148/radiol.2020191145 · External reference

10.1148/radiol.231319

10.1148/radiol.231319 · External reference

10.1016/j.diii.2022.10.008

10.1016/j.diii.2022.10.008 · External reference

10.1016/s1470-2045(18)30413-3

10.1016/s1470-2045(18)30413-3 · External reference

A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer

2021 · External reference

10.1038/s43018-022-00416-8

10.1038/s43018-022-00416-8 · External reference

10.1158/1078-0432.ccr-24-1926

10.1158/1078-0432.ccr-24-1926 · External reference

10.1016/j.crad.2022.12.013

10.1016/j.crad.2022.12.013 · External reference

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach

10.1136/jitc-2021-002545 · 2021 · External reference

10.1007/s00259-021-05509-7

10.1007/s00259-021-05509-7 · External reference

10.1186/s41073-019-0064-8 · Admitted local publication